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Abstract
Aims Visual guidance through echocardiography and
fluoroscopy is crucial for a successful transseptal punc-
ture (TSP) in a prespecified region of the fossa ovalis.
The novel EchoNavigator system Release II (EchoNav II,
Philips Healthcare, Andover, Massachusetts, USA) enables
the real-time fusion of fluoroscopic and echocardiographic
images. We evaluated this new imaging method in respect
to safety and efficacy of TSP during MitraClip implantation
and left atrial appendage closure.
Methods Forty-four patients before (–EchoNav) and 44 pa-
tients after (+EchoNav) the introduction of real-time fusion
were included in our retrospective, single-centre study. The
primary endpoint was the occurrence of adverse events due
to TSP. Secondary endpoints were successful puncture at
the prespecified region and time until TSP (min).
Results In both groups TSP was performed successfully
in the prespecified region and no adverse events occurred
during or due to the accomplishment of TSP. Time until
TSP was significantly reduced in the +EchoNav group in
comparison with the EchoNav group (18.48 ± 5.62 min vs.
23.20 ± 9.61 min, p = 0.006).
Conclusions Real-time fusion of echocardiography and flu-
oroscopy proved to be as safe and successful as standard
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best practice for TSP. Moreover, efficacy was improved
through significant reduction of time until TSP.
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implantation · Left atrial appendage closure · Transseptal
puncture
Introduction
Percutaneous interventions such as MitraClip (Abbott Vas-
cular, Santa Clara, California, USA) implantation and left
atrial appendage (LAA) closure require a precise transsep-
tal puncture (TSP) in a prespecified region of the inter-
atrial septum [1, 2]. Therefore, visual guidance through 2D
and/or 3D echocardiography in addition to fluoroscopy is
essential for a successful performance, since only echocar-
diography depicts anatomic soft tissue structures [3].
Until now, transoesophageal echocardiography (TEE)
images/measurements and fluoroscopy are displayed on
separate monitors and the interventionalist has to merge
this information mentally. This mental coordination of
both modalities is a challenging task [4, 5]. A novel
imaging technology combines real-time echocardiographic
and fluoroscopic images (EchoNavigator system Release II
(EchoNav II), Philips Healthcare, Andover, Massachusetts,
USA), presenting both in an interactive view (Figs. 1
and 2). To date this imaging technique in adult patients
has been described in case reports only [6, 7]. In this
observational study, we report data regarding the safety
and efficacy of performing TSP with the guidance of real-
time fused echocardiographic and fluoroscopic images for
the first time.
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Fig. 1 Transseptal puncture
is demonstrated during LAA
closure guided with EchoNav II.
Transoesophageal echocardio-
gram in short-axis view shows
tenting (*) of the interatrial
septum on the left side (a).
EchoNavigator system Re-
lease II allows real-time fusion
of echocardiographic and fluo-
roscopic images (b). AV aortic
valve, IAS intra-atrial septum,
LA left atrium, RA right atrium;
Arrows are pointing at the TSP
sheath
Fig. 2 Transseptal puncture
is depicted during LAA clo-
sure guided with EchoNav II.
Transoesophageal echocardio-
gram in bicaval view shows
tenting (*) of the interatrial
septum (a); b reflects the cal-
ibration with the TEE probe
and the 2D TEE image in the
same anatomical direction as
the C arm; c displays real-time
fusion of echocardiographic and
fluoroscopic images. AV aortic
valve, IAS intra-atrial septum,
LA left atrium, RA right atrium,
SVC superior vena cava





The recently introduced EchoNav II allows the display
of fluoroscopic and echocardiographic images in real-time
overlay. For a successful real-time fusion, the echocardiog-
raphy probe needs to be localised and tracked in respect to
the fluoroscopy C-arm angulation which is achieved with
a calibration algorithm. After successful co-registration, the
movements of the C-arm and the TEE probe are detected,
and real-time overlay of echocardiography and fluoroscopy
is updated. Additional markers can be set for better visual
guidance [8]. These markers serve as orientation. They are
not combined with automatic tissue tracking and therefore
remain static within the fluoroscopic picture. Compared
with these static markers, the real-time fusion imaging gives
continuously exact echo data within the fluoroscopic image
allowing precise tracking of the soft tissue anatomy during
breathing and heart movement on the fluoroscopic image.
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Study design
Real-time fusion was introduced in our clinic in September
2014. From September 2014 until February 2015 65 pa-
tients received either a MitraClip or a LAA occluder (Am-
platzer Cardiac Plug, St Jude Medical, St. Paul, Minnesota,
USA) implantation. A total of 44 interventions were per-
formed with the guidance of real-time fused echocardio-
graphic and fluoroscopic images and by a fixed team of
always the same interventionalist and experienced echocar-
diographer (+EchoNav group). The second structural team
in our institution is mainly working without echonaviga-
tion, therefore follows a different strategy and is less ex-
perienced with echonavigation. From February 2013 to
September 2014, 44 consecutive patients matching the type
of procedure and the team members were defined as the
control group (–EchoNav group). Therefore, a total of
88 patients were included in the observational single-centre
analysis; 16 patients out of each group received a MitraClip
implantation and 28 patients LAA closure (Fig. 3). Inter-
ventions started with arterial and venous access according
to local standard operating procedures for MitraClip and
LAA closure. After inserting the TEE probe, calibration
of fluoroscopy and TEE probe was performed during stan-
dard rotation of the C-arm for the TSP sheath placement
and orientation in the superior vena cava. Calibration was
achieved within a few seconds (<10 s). Afterwards TSP
was performed in LAO 45° C-arm angulation with a real-
time overlay of 110° TEE image of the left and right atrium
and the atrial septum. While Fig. 1 shows TSP in the short-
Fig. 3 Consort diagram gives
an overview of allocated pa-
tients for both, +EchoNav II
group (with application of
EchoNav II during MitraClip
or LAA closure procedures)
and -EchoNav II group (without
application of EchoNav II dur-
ing MitraClip or LAA closure
procedures). LAA left atrial ap-
pendage, EchoNav II Echonavi-
gator system Release II
axis view, Fig. 2 demonstrates the bicaval view during TSP.
Both views were used for image registration and fusion.
TSP was aimed inferiorly and posteriorly for LAA closure
and at a height of 4.0–5.0 cm above the mitral valve annulus
plane for MitraClip. The location of septal puncture was
re-evaluated directly after sheath placement. Success was
thereby defined as inferior and posterior sheath placement
within the fossa ovalis for LAA closure and as sheath height
of 4–5 cm above the mitral valve annulus for the MitraClip
procedure.
The primary endpoint was considered to be the occur-
rence of adverse events during the performance of TSP.
Adverse events were defined as pericardial effusion, stroke,
air embolism, arrhythmia and death. Secondary endpoints
were successful puncture at the prespecified region and
time until TSP (min). Time until TSP comprised the in-
terval from femoral vascular access in local anaesthesia
until successful puncture of the septum in the prespeci-
fied region. The retrospective analysis was approved by the
ethics committee of the Heinrich Heine University Düssel-
dorf (NCT02608008).
Statistical analysis
The analysis was performed with SPSS for Windows
PASW statistic, version 20.0.0.0 (SPSS Inc., Chicago,
Illinois). Datasets were statistically analysed by the inde-
pendent samples Student’s t-test. For categorical baseline
characteristics of the patients and procedural outcome the
chi-square test was calculated. Continuous data were ex-
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Male gender, n (%) 25 (56.81%) 26 (59.09%) 0.83
Age, years ± SD 77 ± 7.22 75.77 ± 8.11 0.182**
Height, cm ± SD 169 ± 9.30 170 ± 8.78 0.526**
Weight, kg ± SD 78.31 ± 12.13 78.86 ± 15.13 0.852**
Chronic heart failure, n (%) 28 (63.63%) 25 (56.81%) 0.51
Chronic kidney disease, n (%) 29 (65.90%) 22 (50%) 0.13
Atrial fibrillation, n (%) 42 (95.45%) 37 (84.09%) 0.08
Coronary artery disease, n (%) 31 (70.45%) 33 (75%) 0.63
Prior myocardial infarction, n
(%)
31 (70.45%) 28 (63.63%) 0.50
Previous CABG, n (%) 9 (20.45%) 10 (22.72%) 0.80
Previous PCI, n (%) 28 (63.63%) 25 (56.81%) 0.51
Hypercholesterolaemia, n (%) 23 (52.27%) 26 (59.09%) 0.60
Hypertension, n (%) 40 (90.90%) 41 (93.18%) 0.69
Diabetes mellitus, n (%) 12 (27.27%) 14 (31.81%) 0.64
COPD, n (%) 8 (18.18%) 9 (20.45%) 0.79
Aspirin, n (%) 17 (38.63%) 27 (61.36%) 0.86
P2 Y12 inhibitor, n (%) 18 (40.91%) 14 (31.81) 0.38
OAC/NOAC, n (%) 27 (61.36%) 19 (43.18%) 0.09
DAPT, n (%) 8 (18.18%) 3 (6.82%) 0.11
Triple therapy, n (%) 5 (11.36%) 3 (6.82%) 0.46
SD standard deviation, COPD chronic obstructive pulmonary disease, PCI percutaneous coronary intervention, CABG coronary artery bypass
graft, OAC oral anticoagulants, NOAC novel oral anticoagulants, DAPT dual antiplatelet therapy
*Pearson’s chi-squared test
**independent samples Student’s t-test
pressed as mean and standard deviation. P-values below
0.05 were assumed to be significant.
Results
Patient characteristics
The baseline characteristics of the patients are depicted in
Table 1. There were no significant differences between both
groups.
Primary endpoints
No adverse events occurred during or due to TSP in
both groups (Table 2). Two adverse events occurred
after transseptal puncture: An LAA-Occluder device was
dislocated and successfully retrieved from the left atrium
with a standard snare in the +EchoNav group, and an in-
termittent third-degree AV block occurred periprocedurally
during LAA closure in the –EchoNav group.
Secondary endpoints
All TSP were performed successfully in both groups (suc-
cess rate 100% in +EchoNav/–EchoNav group). Fig. 4
shows the distribution of time until TSP as a box plot
with and without the use of the EchoNavigator System Re-
lease II. Time until successful TSP was significantly de-
creased in the +EchoNav group in comparison with the
–EchoNav group (18.48 ± 5.62 min vs. 23.20 ± 9.61 min,
p = 0.006).
Discussion
Fusion of different imaging modalities is a novel approach
to facilitate interventions in structural heart diseases. The
first technical attempts were able to show markers on fluoro-
scopic images in real-time, which have been placed within
echocardiographic images (EchoNav I, Echonavigator Sys-
tem Release I, Philips Healthcare, Andover, Massachusetts,
USA) [9]. A previously published study reported benefits
using EchoNav I during MitraClip implantation. Although
the radiation dose was almost similar in the +/–EchoNav
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Successful TSP, n (%) 44 (100%) 44 (100%)
Air embolism, n 0 0
Pericardial effusion, n 0 0
Arrhythmia, n 0 0
Stroke, n 0 0
Death, n 0 0
TSP transseptal puncture
group, a trend in minimising procedural time could be ob-
served [10]. Another recent study showed that EchoNav I
guidance reduces the radiation dose and the fluoroscopy
time during LAA closure without increasing the overall
procedure time and the rate of periprocedural complications
[11].
Advancement in technology leads to EchoNav II. In ad-
dition to markers, this tool simultaneously presents the
echocardiographic image as overlay on the fluoroscopic im-
ages. Until now, only case reports have been published
which highlight the precision and features of real-time fu-
sion of echocardiographic and fluoroscopic images. One re-
port depicted possible advantages of using EchoNav II dur-
ing TSP in general [7]. Another case report presented the
successful application of EchoNav II during the complex
procedure of transapical mitral valve-in-valve implantation
Fig. 4 The distribution of time until TSP is shown as a box plot with
and without the use of the EchoNavigator System Release II. The bars
represent the whiskers from the minimum to the maximum of all data
of the respective group. The interquartile range (IQR) is 6.75 for the
+EchoNav and 14 for the –EchoNav group. The median was deter-
mined as 18.5 min for the +EchoNav and 21.0 min for the –EchoNav
group. Time until transseptal puncture (TSP) was significantly reduced
in the +EchoNav group compared with the –EchoNav group (*p =
0.006 for an independent-samples t-test)
of a Sapien III prosthesis (Edwards Lifesciences, Irvine,
California, USA) [6]. Furthermore, the use of EchoNav II
has been described as feasible and safe in paediatric patients
with congenital heart diseases such as atrial sepal defect
[12]. Hereby, the use of fusion imaging reduced radiation
dose and fluoroscopy time whereas the overall procedural
time remained the same.
However, no systematically analysed data have been
reported so far in adults. Therefore we aimed to investigate
the application of EchoNav II guidance of TSP during Mi-
tra-
Clip procedure and LAA closure in a relevant cohort
of patients and on the performance of TSP as a pivotal
periprocedural step. Our retrospective analysis of 88 pa-
tients revealed the following: No adverse events during
or due to TSP in the +EchoNav and in the –EchoNav
group, thus showing safety of the technology, a success
rate of 100% of TSP within the prespecified region in the
+EchoNav and in the –EchoNav group and a significant
reduction of time until successful TSP in the +EchoNav
group compared with the –EchoNav group, thus showing
efficacy.
Two adverse events occurred after and independently
from TSP during LAA closure. LAA-Occluder dislocation
occurred in the +EchoNav group and an intermittent third-
degree AV-block occurred periprocedurally during LAA
closure in the –EchoNav group. Concerning occurrence
and characteristics of adverse events they are consistent
with results from earlier studies [13, 14]. Time to TSP of
around 20 min seems to be quite long at first sight, but as
is stated in the Methods section, we started to count from
the exact beginning of the procedure with local anaesthesia.
In summary, the application of real-time fused echocardio-
graphic and fluoroscopic images for the guidance of TSP
can be regarded as safe and efficient.
Looking into the future of fusion imaging we believe
that the current version could be improved by displaying
markers, which move with systole and diastole and breath-
ing motion (tissue tracking). Moreover, automatic forma-
tion of 3D heart models with real-time overlay could im-
prove orientation. The next developmental steps could also
be automatic measurement algorithms (LAA annulus and
landing zone, aortic annulus, sinus of Valsalva etc.). All
this could increase relevance and benefit of this technical
development.
Limitations
We determined TSP as a crucial step in several structural
heart interventions. As it is a standardised manoeuver,
duration of TSP, success of TSP and adverse events can
be analysed precisely. Since our study focused only on
136 Neth Heart J (2017) 25:131–136
LAA closure and MitraClip procedures with the inclusion
of 88 patients in a retrospective fashion, it is underpow-
ered concerning safety. However, our results allow a robust
statement concerning efficacy and give a strong indication
concerning safety. Larger randomised trials are needed to
confirm overall benefits for the MitraClip procedure as well
as for LAA closure using EchoNav II. Moreover its value
for other structural interventions with TEE guidance should
be analysed in the future.
Since we conducted a retrospective cohort study, learn-
ing curve has to be discussed. However, the highly ex-
perienced team members (echocardiographer and inter-
ventionalist) had conducted several hundred TSP proce-
dures before initiation of Echonav II and therefore have
reached the flat part of their learning curve concerning TSP.
The combination of echocardiographic information within
fluoroscopic images was introduced with EchoNav release I
in 2012. Only static markers could be fused with real-time
fluoroscopic images by then. However, the team was fa-
miliar with imaging characteristics and technical aspects
such as calibration of fluoroscopic and echocardiographic
images in 2014. Therefore, no relevant learning curve has
to be taken into consideration when Release II was intro-
duced. Thus we concluded that the significant reduction in
time until TSP could be attributed to innovation in fusion
technology.
Conclusion
Guidance of TSP with real-time fusion during the MitraClip
procedure and LAA closure proved to be safe and efficient
in terms of reduction of time until TSP. Larger randomised
trials are needed to confirm overall benefits for MitraClip
procedure as well as for LAA closure using real-time fu-
sion.
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